Pathophysiology of plaque instability: Insights at the genomic level

Progress in Cardiovascular Diseases

Volumn 44, Issue 5, 2002, Pages 323-338

  Lopes, Neuza ^a,b   Vasudevan, Sanjay S ^a,b   Alvarez, Rene J ^a,b   Binkley, Philip F ^a,b   Goldschmidt, Pascal J ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROTIC PLAQUE; GENE EXPRESSION; GENE TECHNOLOGY; GENETIC DISORDER; GENETIC RESISTANCE; GENETIC SUSCEPTIBILITY; GENOMICS; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RUPTURE; THROMBOEMBOLISM;

EID: 0036098205     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2002.125097     Document Type: Article

References (164)

1. The atherosclerosis epidemic: Methodology, nosology, and clinical practice
2. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-Year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease
3. Alternative projections of mortality and disability by cause 1990- 2020. Global Burden of Disease Study
4. Cardiovascular disease burden increases, NIH funding decreases
5. Shattuck Lecture - Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities
6. Natural history and histological classification of atherosclerotic lesions: An update
7. The pathogenesis of coronary artery disease and the acute coronary syndromes
8. The pathogenesis of coronary artery disease and the acute coronary syndromes
9. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association
10. A definition of advanced arteriosclerosic lesions and a classification of arteriosclerosis
11. The role of plaque rupture and thrombosis in coronary artery disease
12. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions
13. Atherosclerosis - An inflammatory disease
14. The unstable atheroma
15. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death
16. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction
17. Pathophysiology of restenosis: Interaction of thrombosis, hyperplasia, and/or remodeling
18. Restenosis following coronary angioplasty: Clinical presentations and therapeutic options
19. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death
20. Pathophysiology and clinical significance of atherosclerotic plaque rupture
21. Coronary plaque disruption
22. Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes
23. Pathogenesis of plaque disruption
24. Cardiac lesions in fatal cases of recent myocardial ischaemia from a coronary care unit
25. Atherosclerosis
26. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
27. Reduction of stroke after myocardial infarction with Pravastatin in the Cholesterol and Recurrent Events (CARE) study
28. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
29. The discovery and development of HMG-CoA reductase inhibitors
30. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/Tex CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
31. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease
32. Current perspectives on statins
33. Cholesterol-lowering and the use of health care resources: Results of the Scandinavian Sinvastatin Survival Study (4S)
34. Fifteen-year mortality in Coronary Drug Project Patients: Long term benefit with niacin
35. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease
36. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial
37. Atherosclerosis: The road ahead
38. Changing concepts of atherogenesis
39. Vasoconstriction: A new activity for platelet-derived growth factor
40. Extracellular matrix modulates macrophage functions characteristic to atheroma: Collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro
41. Cloning of a disintegrin metalloproteinase that processes precursor tumour necrosis factor-(alpha)
42. Expression of a disintegrin-like protein in cultured human vascular cells and in vivo
43. Matrix metalloproteinases and cardiovascular disease
44. A metalloproteinase disintegrin that releases tumor-necrosis factor-(alpha) from cells
45. Atherosclerotic plaque caps are locally weakened when macrophage density is increased
46. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques
47. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling
48. Mechanisms of acute coronary syndromes and the potential role of statins
49. Effects of lipid-lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal or moderately elevated cholesterol levels: The Regression Growth Evaluation statin Study (REGRESS)
50. Pleiotropic effects of statins and their clinical significance
51. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence
52. Plaque angiogenesis and atherosclerosis
53. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin- 1 beta
54. Apoptosis in atherogenesis: Implications for plaque destabilization
55. Apoptosis in human atherosclerosis and restenosis
56. Macrophage foam cells from experimental atheroma constitutively produces matrix-degrading proteinases
57. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
58. Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis
59. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk 2 inhibitors
60. Matrix metalloproteinases and cardiovascular disease
61. The extracellular matrix as a cell cycle control element in atherosclerosis and restenosis
62. Inhibition of vascular smooth muscle cell growth by inhibition of fibronectin matrix assembly
63. Control of adhesion-dependent cell survival by focal adhesion kinase
64. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells
65. Fas mediated apoptosis in accelerated graft arteriosclerosis
66. Human transplant coronary artery disease: Pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy
67. Oxidized LDL activates Fas-mediated endothelial cell apoptosis
68. Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells
69. THP-1 monocytic leukemia cells express Fas ligand constitutively and kill Fas-positive Jurkat cells
70. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-react with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1
71. Role of macrophage colony-stimulating factor in atherosclerosis: Studies of osteopetrotic mice
72. Activated monocytes induce smooth muscle cell death - Role of M-CSF and cell contact
73. ApoEdeficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree
74. The unstable atheroma
75. Fas ligand/Fasmediated apoptosis in human coronary artery smooth muscle cells: Therapeutic implications of fratricidal mode of action
76. Biologic effect and molecular regulation of vascular apoptosis in atherosclerosis
77. Vasoreactivity of the culprit lesion in unstable angina
78. Redox signaling of the arteriolar myogenic response
79. NAD(P)H Oxidase: Role in cardiovascular biology and disease
80. Renin angiotensin system and atherosclerotic vascular disease
81. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone
82. The multiple actions of angiotensin II in atherosclerosis
83. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells
84. Angiotensin II and atherosclerosis
85. Protection against ischemia: A physiological function of the renin-angiotensin system
86. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction
87. Current perspective on the role of apoptosis in atherothrombotic disease
88. Prothrombotic effects of angiotensin
89. Angiotensin II induces PAI-1 expression through MAP kinase-dependent, but TGF beta and P13 kinase-independent pathway
90. Upregulation of PAI-1 is mediated through TGF beta/SMAD pathway in transplant arteriopathy
91. Binding of mutant tissue-type plasminogen activators to human endothelial cells and their extracellular matrix
92. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: Direct link between endothelial dysfunction and atherothrombosis
93. Acute psychological stress decreases plasma tissue plasminogen activator (tPA) and tissue plasminogen activator/plasminogen activator inhibitor-1 (tPA/PAI-1) complexes in cardiac patients
94. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study
95. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-I levels in acute myocardial infarction
96. Stimulation of macrophage urokinase expression by polyanions is protein kinase C-dependent and requires protein and RNA synthesis
97. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes
98. Genetic polymorphisms and risk of coronary artery disease
99. Genetic analysis of atherosclerosis: A research paradigm for the common diseases
100. Patterns of single nucleotide polymorphisms in canditate genes for BP homeostasis
101. Genomics gene expression and DNA arrays
102. Family history as an independent risk factor for incident coronary artery disease in a high-risk cohort in Utah
103. Genetic-epidemiologic study of early-onset ischemic heart disease
104. Genetic predisposition to coronary artery disease
105. Genetic susceptibility to death from coronary heart disease in a study of twins
106. Familial hypercolesterolemia
107. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis
108. A common variant in the gene for lipoprotein lipase (Asp9 → Asn). Functional implications and prevalence in normal and hyperlipidemic subjects
109. Mutations in the gene for lipoprotein lipase. A cause for low HDL cholesterol levels in individuals heterozygous for familial hypercholesterolemia
110. ABCA 1 single nucleotide polymorphisms. Snipping at the pathogenesis of atherosclerosis
111. A point mutation in ABC 1 gene in a patient with severe premature coronary heart disease and mild clinical phenotype of Tangier disease
112. Novel polymorphisms in promoter region of atp binding assette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy
113. ABC 1. The gatekeeper for eliminating excess tissue cholesterol
114. Homogeneous assay based on 52 primer sets to scan for mutations of the ABC1 gene and its application in genetic analysis of a new patient with familial high-density lipoprotein deficiency syndrome
115. Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and ABC-1-deficient mice
116. The natural history of homocystinuria due to cystathionine (beta)synthase deficiency
117. Impaired elastogenesis in Hurler disease: Dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly
118. The LDL receptor locus in familial hypercholesterolemia: Mutational analysis of a membrane protein
119. Identification of genes potentially involved in rupture of human atherosclerotic plaques
120. Allele-specific regulation of matrix metalloproteinase- 12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease
121. Polymorphism in matrix metalloproteinase gene promoters: Implication in regulation of gene expression and susceptibility of various diseases
122. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction
123. Characterization of mouse thrombospondin 2 sequence and expression during cell growth and development
124. Diversity of function is inherent in matricellular proteins: An appraisal of thrombospondin 1
125. Light microscopic immunolocation of thrombospondin in human tissues
126. Cartilage oligomeric matrix protein (thrombospondin-5) is expressed by human vascular smooth muscle cells
127. Characterization of single-nucleotide polymorfism in coding regions of human genes
128. Molecular genetics and gene expression in atherosclerosis
129. Identification of a coordinate regulator of interleukins 4, 13 and 5 by cross-species sequence comparations
130. Genomic circuits and the integrative biology of cardiac disease
131. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics
132. The Human platelet alloantigenes, Pla1 and Ppla2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing
133. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
134. Higher prevalence of GPIIIa Pa 2 polymorphism in siblings of patients with premature coronary heart disease
135. A polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middleaged men who died suddenly
136. Integrin polymorphisms as risk factors for thrombosis
137. The leu33/Pro polymorphism (PA1/PA2) of the glycoprotein IIIa (Gpllla) receptor is not related to myocardial infarction in the ECTIM Study: Estude Cas-Teoins de I Infarctus du Myocarde
138. Al/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: A case-controlled study
139. A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke and venous thrombosis
140. Platelet PA2 allele and incidence of coronary heart disease: Results from the Atherosclerosis Risk in Communities (ARIC) Study
141. Platelet GP IIIa P(A) polymorphisms display different sensitivities to agonists
142. The PA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation
143. The P(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions
144. Platelets polymorphisms and ischemic heart disease: Moving beyond traditional risk factors
145. Genetics of coronary heart disease: Current knowledge and research principles
146. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction
147. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
148. Genetic polymorphism of 5, 10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease
149. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease
150. Genetic modifiers of atherosclerosis in mice
151. Phenotype-driven genetic approaches in mice
152. Atherosclerotic plaque rupture in the apoplipoprotein E knockout mouse
153. Genetic modifiers of atherosclerosis in mice
154. Genes and physiology: Molecular physiology in genetically engineered animals
155. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells
156. ApoEdeficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree
157. Macrophage phenotype in mice deficient in both macrophage-colony-stimulating factor (op) and apolipoprotein E
158. Polymorphisms in endothelial nitric oxide synthase and atherogenesis
159. Identification of genes potentially involved in rupture of human atherosclerotic plaques
160. Absence of perilipin results in leanness and reverses obesity in Lepr (db/db) mice
161. Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity
162. Differential display identification of 40 genes with altered expression in activated human smooth muscle cells. Local expression in atherosclerotic lesions of smags, smooth muscle activation-specific genes
163. Large-scale gene expression analysis of cholesterol-loaded macrophages